Jazz Pharmaceuticals plc diskutieren
Jazz Pharmaceuticals plc
WKN: A1JS1K / Symbol: JAZZ / Name: Jazz Pharma / Aktie / Pharmazeutika / Mid Cap /
139,50 €
-1,78 %
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Royal Bank of Canada from $174.00 to $175.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Royal Bank of Canada from $175.00 to $179.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at TD Cowen from $200.00 to $195.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Robert W. Baird from $154.00 to $162.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock, down previously from $166.00.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $179.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $175.00 price target on the stock, up previously from $140.00.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $170.00 price target on the stock, up previously from $130.00.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Needham & Company LLC from $205.00 to $210.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at JPMorgan Chase & Co. from $200.00 to $209.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Royal Bank of Canada from $179.00 to $178.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $176.00 price target on the stock, up previously from $163.00.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $210.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Truist Financial Co. from $220.00 to $230.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $179.00 price target on the stock, up previously from $145.00.
Ratings data for JAZZ provided by MarketBeat
Neueste Beiträge
Sanford_C__Bernstein in KLA-Tencor Corp. diskutieren